Efficacy, Safety, and Immunogenicity of an Inactivated, Adjuvanted Enterovirus 71 Vaccine EV71vac in Infants and Children: A Multi-Region, Double-Blinded, Randomised, Placebo-Controlled, Phase 3 Trial
Toan Trong Nguyen,Cheng-Hsun Chiu,Chien-Yu Lin,Nan-Chang Chiu,Po-Yen Chen,Thi Tuong Vy Le,Dang Ngan Le,An Han Duong,Van Luan Nguyen,Thi Nguyet Huyn,Huu Khanh Troung,Trong Lan Phan,Thi Thanh Thao Nguyen,Shin-Ru Shih,Chung-Guei Huang,Yi-Jen Wen,Erh-Fang Hsieh,Stanley Chang,Charles Chen,I-Chen Tai,Li-Min Huang
DOI: https://doi.org/10.2139/ssrn.4000536
2022-01-01
SSRN Electronic Journal
Abstract:Background: Children are susceptible to severe or fatal enterovirus 71 (EV71) infections. We evaluated the efficacy, safety, and immunogenicity of EV71vac, an aluminium phosphate-adjuvanted inactivated EV71 vaccine in children 2 months to 5 years old.Methods: We conducted a randomised, double-blinded, placebo-controlled, phase 3 trial at 5 hospitals in Taiwan and 2 in Vietnam. Children 2 months to 5 years old were stratified by country and age, and randomly assigned (1:1) to receive two doses of EV71vac or placebo via intramuscular injection 56 days apart. Children 2 months to 1 year old received a third booster dose on day 366. The primary endpoint was the clinical efficacy of the total vaccinated cohort against EV71 associated diseases during the follow-up period, from 14 days after the second dose to when 15 cases of EV71 infections were confirmed. Our safety analysis included all participants who received at least one dose of EV71vac. This trial is registered with ClinicalTrials.gov, NCT03865238.Findings: Between April 23, 2019, and December 25, 2019, 3049 children were randomised and vaccinated: 1521 children in the EV71vac group and 1528 in the placebo group. By May 20, 2021, our primary efficacy analysis included 2959 children, with 1476 children in the EV71vac group and 1483 children in the placebo group. The vaccine efficacy of EV71vac was 96·8% (95% CI 85·5–100) against EV71 associated diseases (p<0·0001). The percentage of participants who reported solicited adverse events were comparable in both groups: 56·9% in the EV71vac group and 55·8% in the placebo group. Almost all reported solicited adverse events were mild and self-limited.Interpretation: EV71vac is safe, well-tolerated, and highly effective in preventing EV71 associated diseases in children 2 months to 5 years old.Trial Registration Details: This trial is registered with ClinicalTrials.gov, NCT03865238.Funding Information: Medigen Vaccine Biologics Corporation and A+ Industrial Innovative R&D Program of the 66 Ministry of Economic Affairs, Taiwan.Declaration of Interests: Nguyen TT , Chiu CH, Lin CY, Chiu NC, Chen PY, Le TTV, Le DN , Duong AH , Nguyen VL, Huynh TN, Truong HK , Shih SR, Huang CG, and Chang S and Huang LM declared that they have no known competing financial interests or personal relationships that could influence the work reported in this paper; Chen C, Weng YJ, Hsieh EF and Tai IC are employees of Medigen Vaccine Biologics Corporation and reported grants from A+ Industrial Innovative R&D Program of the Ministry of Economic Affairs, Taiwan, during the conduct of the study. Parents/guardians understood the full content of the written informed consent and signed it on behalf of their children.Ethics Approval Statement: The trial protocol (appendix) was approved by the Taiwan Food and Drug Administration and the ethics committees at the participating sites. The ethical review boards were these following institutes: National Taiwan University Hospital Research Ethics Committee (Taipei, Taiwan), Mackay Memorial Hospital Institutional Review Board (Taipei, Taiwan), Chang Gung Medical Foundation Institutional Review Board (Taoyuan, Taiwan), Taichung Veterans General Hospital Institutional Review Board (Taichung, Taiwan), Institutional Ethics Committee in 120 Biomedical Research, Pasteur Institute in Ho Chi Minh City (Ho Chi Minh, Vietnam), and the of Health's National Ethics Committee in Biomedical Research (Hanoi, Vietnam). The trial complied with the guidelines set by the International Council for Harmonisation (ICH) for Good Clinical Practice (GCP).